EPCORE™FL-2: This study will assess how safe and effective immunotherapy (called Epcoritamab) is when given in addition to R2 (a combination of Rituximab and Lenalidomide), compared to chemoimmunotherapy, in people with previously untreated follicular lymphomaA Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma

Inclusion

• Diagnosis of follicular lymphoma (FL).
• Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
• Are willing and able to comply with procedures required in the protocol.
• Must have stage, II, III or IV disease.
• Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.

• Has one or more target lesions:

  • A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
  • >=1 measurable nodal lesion (long axis >1.5cm) or >=1 measurable extra-nodal lesion (long axis >1.0 cm) on CT scan or MRI
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: [Arm B] at the discretion of the Investigator, and rituximab and lenalidomide (R2) [Arm C].
• Have laboratory values meeting the criteria in the protocol.